The Radix BioSolutions management team has experienced scientists and successful business talent. They are backed by a dedicated group of individuals, principally scientists by training, who are focused on applying the latest technologies to enhance the research capabilities of our customers.


Scott Edelman-CEO

Mr. Edelman has been the CEO of Radix since January 2014, and has over 30 years experience in managing and profitably growing early stage businesses both in the software and biotech industries.

Previous to Mr. Edelman's involvement with Radix, Scott was one of the founding members and CEO of AdiCyte Inc., a Tucson-based, start-up for adipose tissue and stem cell banking starting in late 2011. From 2003 through 2008, Mr. Edelman was CEO of CellzDirect, a hepatic cell product and contract research organization that grew profitability from zero to $19 million in revenues that was sold to Life Technologies in 2008.

Mr. Edelman has a BS in Business from Pennsylvania State University, is an active angel investor in numerous early stage enterprises, and resides in Tucson, Arizona.


Kerry Oliver, Ph.D.-President, CSO

Dr. Oliver has over thirty years of academic, government, and industry experience in assay development. This work has spanned a broad range of disciplines including immunology and signal transduction biochemistry, diagnostic device development, and CRO services supporting various stages of therapeutic development. Following his Ph.D. in immunology from The University of Texas Southwestern Medical Center at Dallas, under the direction of Dr. Ellen Vitetta, Kerry received his postdoctoral training examining signal transduction pharmacology at the National Institutes of Health. Subsequently, he spent three years in drug discovery.

In 1997, Dr. Oliver joined the R&D department at Luminex during its initial development of the xMAP® diagnostic platform. His initial responsibility at Luminex was to lead a team of assay development scientists to showcase the capabilities of the platform to early adopters of xMAP® technology. In addition, he served as a liaison with key customers and strategic partners to expedite their adoption and commercialization of the platform.

In late 2001, Dr. Oliver founded Radix BioSolutions to satisfy unmet customer needs with custom molecular and immunoassay development, validation, and manufacturing. Radix products are used for customer’s in-house research, clinical trials, and environmental threat assessment and testing.



R. Jerrold Fulton, Ph.D.

Dr. Fulton received his B.A. in biology at The University of Texas at Austin in 1975 and went on to earn his Ph.D. in immunology at The University of Texas Southwestern Medical Center at Dallas in 1980 under advisor Dr. David Hart. His postdoctoral work in immunochemistry and molecular biology was completed at Washington University in St. Louis, Missouri in the laboratories of Dr. Joseph Davies and Dr. Henry Huang. He served five years on the faculty of the Department of Microbiology at The University of Texas Southwestern Medical Center at Dallas. He was a co-founder of Luminex Corporation, Member of the Board of Directors, and Vice President for Research. He is a co-founder, partner, and Member of the Board of Directors of Radix BioSolutions and has written a number of scientific publications.